Navigation Links
Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
Date:3/12/2009

percent with TRA (43 percent reduction).

TRAP-induced platelet aggregation inhibition was also measured. In those receiving the three oral loadings doses, platelet inhibition of greater than or equal to 80 percent was seen in 42.9 percent, 52.9 percent and 96.3 percent of study patients at each respective dose 120 minutes post-TRA administration. In maintenance doses, inhibition greater than or equal to 80 percent was seen in 90.9 percent, 100 percent and 100 percent of patients at each respective dose at 30 and 60 days compared to 9.1 and 11.1 percent at 30 and 60 days for patients receiving standard of care.

About the Phase III Trials

TRA is currently being evaluated in two large-scale multinational, randomized, double-blind, placebo-controlled Phase III clinical trials.

The Phase III Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2P-TIMI 50) trial is a multinational, randomized, double-blind, placebo-controlled study in approximately 19,500 patients with prior MI or stroke, as well as patients with existing peripheral arterial disease. Patients will be randomized to either placebo plus standard medical care (including aspirin and clopidogrel) or to TRA once daily plus standard medical care. This Phase III trial uses the 2.5 mg maintenance dose. The primary endpoint of the trial is the composite of cardiovascular death, MI, urgent coronary revascularization or stroke. The key secondary endpoint is the composite of cardiovascular death, MI or stroke. Patients will be followed for a minimum of one year. This Phase III trial is being conducted by the Thrombolysis in Myocardial Infarction (TIMI) Study Group.

The Phase III Thrombin Receptor Antagonist Clinical Event Reduction in acute coronary syndrome (TRA-CER) trial is a multinational, randomized, double-blind, placebo-controlled study in approximately 10,000 patients with non-ST-seg
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
2. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
3. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
4. Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
5. Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting
6. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
7. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
8. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
11. Berlin Hearts EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... , March 31, 2015 MedSpring Urgent Care is pleased ... Dallas/Fort-Worth area of Upper Greenville. The center – ... Dallas location. Knox - ... by the surrounding community since opening last fall. Additional ... the Keller and Las Colinas neighborhoods this ...
(Date:3/31/2015)... -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ("Galmed"), ... and commercialization of a once-daily, oral therapy for ... today announced financial results for the 12 months ... 2014 Highlights: , Hosted a key opinion ... Rohit Loomba, MD, MHSc., who discussed the topic ...
(Date:3/31/2015)... TAMPA, Fla. , March 31, 2015  Oxis ... biotech cancer therapy development and commercialization, announced today Oxis ... of the trading of Oxis common shares on the ... the OTCQB under the symbol OXIS.   ... "As Oxis continues to move forward with its strategies ...
Breaking Medicine Technology:MedSpring Urgent Care Opens New Upper Greenville Location in Dallas 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 3Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 4Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 5Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 6Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 7Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 8Oxis International Inc. Announces Request for Euronext Trading Suspension 2
(Date:3/31/2015)... March 31, 2015 Students, teachers, and ... for education in a drastically different way as current ... learning and training content is being delivered and received. ... by technology in an unprecedented way with education becoming ... Cumavoo, co-founder and CEO, My Mobile University , ...
(Date:3/31/2015)... Clinovo, a leading provider of ... , the premiere voice of Northern California’s Life ... companies. , BayBio brings together the collective ... and productive life science cluster, helping companies grow, ... most pressing challenges. , “We are thrilled ...
(Date:3/31/2015)... March 31, 2015 Dr. Russell Ashinoff is ... Reconstruction. He was recently quoted in an Asbury Park ... lymphatic issues, causing fluid retention and tissue swelling. Dr. ... relieve and / or improve lymphedema symptoms. , ... alleviate the symptoms of lymphedema. The goal is to ...
(Date:3/31/2015)... Dr. Uzma Parvez is having a busy start to ... Grounds Presentations at St. Michael’s Medical Center for attending staff ... The event was attended by a large gathering of students, ... from the Grand Rounds. It was said that it ... while. , Ahead, Dr. Parvez has been invited to ...
(Date:3/31/2015)... 2015 One of the most beautiful and awe-inspiring ... Mount Kilauea on the big island. The big island of ... can see molten lava slowly oozing at your feet in one ... , One place you would never expect to see a live ... of Mission, Texas -- until now. , Members of a local ...
Breaking Medicine News(10 mins):Health News:LTT Global Communications Launches First Asia Holistic Online Learning Platform 2Health News:LTT Global Communications Launches First Asia Holistic Online Learning Platform 3Health News:Clinovo Joins BayBio Membership Program, The Leading Life Science Association in Northern California 2Health News:The Physicians at Plastic Surgery Center Each Have Something to Celebrate This March 2Health News:The Physicians at Plastic Surgery Center Each Have Something to Celebrate This March 3Health News:The Physicians at Plastic Surgery Center Each Have Something to Celebrate This March 4Health News:NJ Top Docs Presents, Dr. Uzma Parvez of Total Pain Care 2Health News:Rare Volcano Constructed inside Gold’s Gym in Mission, Texas 2Health News:Rare Volcano Constructed inside Gold’s Gym in Mission, Texas 3
... the plant that attracts domestic cats like an irresistible ... blood-sucking flies that attack horses and cows, causing $2 ... the word from a report published in ACS, biweekly ... Junwei Zhu and colleagues note that stable flies not ...
... infected with HIV get pregnant more often and suffer pregnancy ... research led by Johns Hopkins investigators. A report ... from 181 patients with HIV, ages 13 to 24, treated ... the Feb. 2 issue of the Journal of the ...
... Johns Hopkins have found a better way to create ... properties of embryonic stem cellsfrom a small blood sample. ... Research , avoids creating DNA changes that could lead ... safer than ones made with previous technologies because they ...
... combination selectively crosses the tight barrier that protects the brain ... brain tumors, a research team led by scientists from The ... January issue of the Journal of Clinical Investigation . ... targeted particles guide payloads to image tumors, treat tumors, or ...
... teens and young women are more likely to get pregnant and ... HIV, a new study finds. Researchers from Johns Hopkins analyzed ... who had been treated at four hospitals over 12 years. More ... for a total of 96 pregnancies. The rate of premature ...
... TUESDAY, Feb. 1 (HealthDay News) -- End-of-life care facilities ... require less-skilled care on the part of the hospice, or ... Under the current Medicare reimbursement system -- which ... -- such patients would likely cost less to care for, ...
Cached Medicine News:Health News:Teens with HIV at high risk for pregnancy, complications 2Health News:Johns Hopkins researchers develop safer way to make induced pluripotent stem cells 2Health News:Targeted particle fools brain's guardian to reach tumors 2Health News:Targeted particle fools brain's guardian to reach tumors 3Health News:Targeted particle fools brain's guardian to reach tumors 4Health News:HIV Linked to Higher Pregnancy Rate in Young Women 2Health News:For-Profit Hospices May Prefer Certain Types of Patients: Study 2Health News:For-Profit Hospices May Prefer Certain Types of Patients: Study 3
Gerald forceps. Insulated....
Cushing forceps. Insulated....
Angled 60 degree blades 5.5 mm....
... Nystagmus when rotated at 8-10 ... by 8" diameter. Light weight ... ball bearings for effortless spin ... 30 inches from patient. Colorful ...
Medicine Products: